title: NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
abstract: The activation of nuclear factor kappa B (NFκB) transcription factor family is considered to have a key role in diffuse large B-cell lymphoma (DLBCL) pathogenesis and is associated with a specific molecular subtype, the activated B-cell-like (ABC) subtype. We evaluated the expression of NFκB by immunohistochemistry in a large series of DLBCL cases. The five different NFκB family members (NFκB1, NFκB2, RELA, RELB, and REL) showed a heterogeneous expression pattern with the vast majority of cases being positive for at least one factor. Two independent series of tumor samples were classified into germinal center B-cell-like (GCB) or ABC subtypes using different approaches, immunohistochemistry, or gene expression profiling, and the expression of NFκB family members was assessed. Notably, no significant differences regarding the expression of the different NFκB members were detected between the two subtypes, suggesting that NFκB signaling is a prominent feature not only in the ABC subtype, but also in the GCB tumors. Of the five transcription factors, only REL expression had a significant clinical impact on R-CHOP-treated diffuse large B-cell lymphoma, identifying a subgroup of patients with superior clinical outcome.
authors.affiliation: 1] Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] Cancer Genomics Group, Valdecilla Biomedical Research Institute (IFIMAV), Santander, Spain.
authors.forename: Lina
authors.initials: L
authors.lastname: Odqvist
authors.affiliation: Pathology Department, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IFIMAV, Santander, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.affiliation: Pathology Department, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IFIMAV, Santander, Spain.
authors.forename: Roxana E
authors.initials: RE
authors.lastname: Sánchez-Pacheco
authors.affiliation: UT MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Ken H
authors.initials: KH
authors.lastname: Young
authors.affiliation: 1] Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain [2] Cancer Genomics Group, Valdecilla Biomedical Research Institute (IFIMAV), Santander, Spain.
authors.forename: Esperanza
authors.initials: E
authors.lastname: Martín-Sánchez
authors.affiliation: Cancer Genomics Group, Valdecilla Biomedical Research Institute (IFIMAV), Santander, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Cereceda
authors.affiliation: Biotechnology Programme, CNIO; Madrid, Spain.
authors.forename: Lydia
authors.initials: L
authors.lastname: Sánchez-Verde
authors.affiliation: Biotechnology Programme, CNIO; Madrid, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Pajares
authors.affiliation: Hospital Virgen de la Salud, Toledo, Spain.
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.affiliation: Hospital Central de Asturias, Oviedo, Spain.
authors.forename: Manuel F
authors.initials: MF
authors.lastname: Fresno
authors.affiliation: Pathology Department, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IFIMAV, Santander, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Mazorra
authors.affiliation: Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Ruíz-Marcellán
authors.affiliation: Oncology-Hematology Area, Instituto Investigación Sanitaria Hospital Universitario Puerta de Hierro-Majadahonda, Calle Joaquín Rodrígo 2, Madrid, Spain.
authors.forename: Margarita
authors.initials: M
authors.lastname: Sánchez-Beato
authors.affiliation: 1] Cancer Genomics Group, Valdecilla Biomedical Research Institute (IFIMAV), Santander, Spain [2] Pathology Department, Hospital Universitario Marques de Valdecilla, Universidad de Cantabria, IFIMAV, Santander, Spain.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000096:biosynthesis*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D016328:NF-kappa B